



IL28B RealFast™ Assay

The accurate way to test the therapeutic response of antiviral therapy in Hepatitis C Virus (HCV) infected patients

Key to a successful antiviral therapy

The IL28B RealFast™ Assay helps to predict the success of antiviral therapy and sustained virologic response (SVR) in HCV infected patients. Chronic HCV infection affects around 1% of the world population and is the leading cause of cirrhosis, liver cancer and liver transplantation. Pegylated interferon/ribavirin (pegIFN/RBV) therapy is the treatment of choice for HCV infection. SVR is dependent on virus genotype as well as on patients' factors including genetic polymorphisms.

The TT>ΔG variant in the *IFNL4* gene is the strongest known host factor for predicting HCV clearance. Genotyping of TT>ΔG helps to predict the outcome of pegIFN/RBV therapy independent of a patient's ethnicity.

The TT>ΔG dinucleotide frame-shift variant appears, if present, in the human *interferon lambda 4 (IFNL4)* gene/pseudogene, which is located upstream of the gene encoding interleukin 28B (IL28B). Homozygous carriers of the favorable TT allele are predisposed to an up to 3-fold higher sustained virological response (SVR) than carriers of the ΔG allele.

ViennaLab RealFast™ Assays

- Fast and easy handling
- Less than 90 min from DNA to result
- Ready-to-use reagents
- Include controls for wild type and mutant genotype
- Compatible with various real-time PCR instruments
- Available in different pack sizes (100 reactions and 32 reactions)

REF:

IL28B RealFast™ Assay: 7-200 (100 reactions)

IL28B RealFast™ Assay: 7-203 (32 reactions)

For more details please visit: www.viennalab.com

ViennaLab RealFast™ Assays for single marker detection (compatible with the D2PCR™ Buffer)

Area	Product	REF 100 / 32 Rxn	Label	Application
Carbamazepine Hypersensitivity	HLA-A3101 RealFast™ Assay	7-640 / 7-643	CE/IVD	Detects the human leukocyte antigen-A (HLA-A) 3101 allele, which is strongly associated with carbamazepine hypersensitivity reactions in Europeans and Japanese
	HLA-B1502 RealFast™ Assay	7-630 / 7-633	CE/IVD	Detects the human leukocyte antigen-B (HLA-B) 1502 allele, which is strongly associated with carbamazepine hypersensitivity reactions in Asian populations
Carbohydrate Intolerance	LCT -13910C>T RealFast™ Assay	7-150 / 7-153	CE/IVD	Detects the most common polymorphism in the <i>lactase (LCT)</i> gene causing lactase non-persistence
Cardiovascular Diseases (CVD)	FGB -455G>A RealFast™ Assay	7-230 / 7-233	CE/IVD	Identifies homozygosity for the -455G>A <i>fibrinogen beta-chain (FGB)</i> allele which may increase susceptibility to atherothrombosis in at-risk patients
	FV Leiden RealFast™ Assay	7-110 / 7-113	CE/IVD	Detects the most common genetic risk factor associated with venous thromboembolism, the 1691G>A mutation in the <i>Factor V (FV)</i> gene
	FXII 46C>T RealFast™ Assay	7-240 / 7-243	CE/IVD	Identifies patients with the unfavorable TT genotype for <i>Factor XII (FXII)</i> , who may have an increased susceptibility to thrombotic disorders
	FXIII V34L RealFast™ Assay	7-250 / 7-253	CE/IVD	Identifies carriers of the protective 34L variant of Factor XIII (FXIII) among at-risk patients of hereditary thrombophilia
	MTHFR 677C>T RealFast™ Assay	7-160 / 7-163	CE/IVD	Detect common mutations in the <i>methylenetetrahydrofolate reductase (MTHFR)</i> gene causing hyperhomocysteinemia, which is a risk factor for cardiovascular disease
	MTHFR 1298A>C RealFast™ Assay	7-170 / 7-173	CE/IVD	
	PAI-1 4G/5G RealFast™ Assay	7-180 / 7-183	CE/IVD	Detects the 4G risk allele in the <i>plasminogen activator inhibitor-1 (PAI-1)</i> gene, associated with cardiovascular disease and pregnancy complications
PTH 20210G>A RealFast™ Assay	7-120 / 7-123	CE/IVD	Detects the second most important genetic risk factor for venous thromboembolism in the <i>prothrombin (PTH)</i> gene	
Genetic Predisposition	HLA-B27 RealFast™ Assay	7-620 / 7-623	CE/IVD	Detects the human leukocyte antigen-B (HLA-B) 27 allele, which is associated with ankylosing spondylitis
Haemochromatosis	HFE C282Y RealFast™ Assay	7-130 / 7-133	CE/IVD	Detect common mutations in the <i>HFE</i> gene causing hereditary haemochromatosis (HH) type 1
	HFE H63D RealFast™ Assay	7-140 / 7-143	CE/IVD	
Pharmacogenetics	HLA-B5701 RealFast™ Assay	7-610 / 7-613	CE/IVD	Detects human leukocyte antigen-B (HLA-B) 5701 allele, which is associated with hypersensitivity to the anti-HIV drug abacavir
	IL28B RealFast™ Assay	7-200 / 7-203	CE/IVD	Detects a dinucleotide frame-shift variant coding for interleukin 28B (IL28B) and helps to predict the therapeutic response in Hepatitis C Virus infected patients
	SLC01B1c.521T>C RealFast™ Assay	7-210 / 7-213	CE/IVD	Detects a variant in human <i>solute carrier organic anion transporter family member 1B1 (SLC01B1)</i> gene in patients who are at higher risk for developing statin-induced myopathy
	VKORC1 -1639G>A RealFast™ Assay	7-190 / 7-193	CE/IVD	Detects the most important polymorphism in the <i>Vitamin K Epoxide Reductase Complex 1 (VKORC1)</i> gene associated with interindividual dose requirements for oral anticoagulants

ViennaLab RealFast™ Assays for multiplex testing - save costs and sample material (compatible with the D2PCR™ Buffer)

Cardiovascular Diseases (CVD)	FV-PTH mpx RealFast™ Assay	7-115 / 7-118	CE/IVD	Simultaneous detection of the most important thrombophilic mutations 1691G>A in the <i>Factor V</i> gene and 20210G>A in the <i>prothrombin</i> gene
	MTHFR mpx RealFast™ Assay	7-165 / 7-168	CE/IVD	Simultaneous detection of the most common two mutations in the <i>MTHFR</i> gene: 677C>T and 1298A>C
COPD/ AAT deficiency	AAT mpx *) RealFast™ Assay	7-265 / 7-268	CE/IVD	Detects *S and *Z variants of the <i>SERPINA1</i> gene predisposing individuals to chronic obstructive pulmonary disease (COPD) and liver disease due to deficiency of alpha-1 antitrypsin (AAT)
Haemochromatosis	HFE mpx RealFast™ Assay	7-135 / 7-138	CE/IVD	Simultaneous detection of the two most common mutations in the <i>HFE</i> gene: H63D and C282Y
Pharmacogenetics	CYP2C9 mpx *) RealFast™ Assay	7-225 / 7-228	CE/IVD	Simultaneous detection of <i>CYP2C9</i> *2 (c.430C>T) and <i>CYP2C9</i> *3 (c.1075A>C) polymorphisms to determine the drug response of known targets, like S-warfarin or phenytoin

*) not suitable for ultrafast cycling on the MIC qPCR Cycler

Additional diagnostic applications that are covered by ViennaLab RealFast™ Assays: Liquid Profiling, Congenital Adrenal Hyperplasia, CYP2D6 CNV determination ^{NEW!}, Covid-19 testing ^{NEW!}.



Manufacturer:

ViennaLab Diagnostics GmbH

Gaudenzdorfer Guertel 43-45

A-1120 Vienna, Austria

www.viennalab.com

t: (+43-1) 8120156-0

e: info@viennalab.com

Distributor:



More details available at www.viennalab.com